Before you buy a vial of the "exercise mimetic" peptide, consider this: a small new study found that elite sprinters and field athletes already carry about 59% more circulating MOTS-c than sedentary young men, and nobody gave them an injection.
The finding comes from a cross-sectional study in Antioxidants (Zhang et al., 2026) from Tianjin University of Sport. It is a small snapshot of 30 people, not a trial. It still adds a useful data point to a peptide that is often marketed as a shortcut to what training already does.
What is MOTS-c?
MOTS-c is a short peptide encoded in mitochondrial DNA rather than the nuclear genome. It belongs to the "mitochondrial-derived peptides," which are described as signaling molecules, or mitokines. The authors call it an exercise-responsive mitokine, meaning its levels appear to shift with physical activity. Its link to metabolism and exercise is why it has picked up the "exercise mimetic" label in online peptide circles.
The paper's own framing is more modest. The authors say the associations between MOTS-c, exercise capacity and antioxidant markers "remain unclear," and that is the gap they set out to address.
The three groups
The researchers recruited 30 healthy males aged 18 to 25 and split them into three groups of 10:
- Elite track and field athletes
- Recreationally active individuals
- Sedentary controls
They measured serum MOTS-c alongside superoxide dismutase (SOD, an antioxidant enzyme) and post-exercise malondialdehyde (MDA, a common marker of oxidative damage to lipids). They also ran a battery of fitness tests: VO2max, forced vital capacity, vertical jump, handgrip strength, back muscle endurance and post-fatigue back muscle force.
The numbers
MOTS-c rose step by step with fitness level:
| Group | Serum MOTS-c (pg/mL) |
|---|---|
| Elite athletes | 507.51 ± 67.42 |
| Recreationally active | 440.32 ± 32.83 |
| Sedentary | 319.31 ± 99.07 |
The difference was statistically significant (p < 0.001). The athlete-versus-sedentary comparison had a Hedges' g of 2.13, a very large effect size. The "59%" figure is simply the athlete average divided by the sedentary average. The active group sat in the middle, roughly 38% above sedentary by the same arithmetic.
What tracked with MOTS-c
Across the whole sample, MOTS-c correlated strongly with several measures (all p < 0.001):
- Absolute VO2max: r = 0.892
- SOD: r = 0.847
- Post-exercise MDA: r = −0.910, so higher MOTS-c went with less oxidative damage after exercise
- Back muscle endurance: r = 0.725
- Post-fatigue back muscle force: r = 0.812
Handgrip strength was the exception. It showed no significant correlation (r = 0.315, p = 0.090). The pattern points more toward endurance and fatigue-related capacity than raw grip strength, though with this sample size that is a tentative reading.
In an exploratory hierarchical regression, post-exercise MDA stayed significantly associated with MOTS-c after adjusting for VO2max. SOD did not. So the link between MOTS-c and lower oxidative damage may not be explained by aerobic fitness alone, but the authors label this analysis exploratory.
Limits you need to know
This is where the headline needs to be read carefully.
- Cross-sectional design. Everyone was measured once. The authors state plainly that the design "precludes causal inference." We cannot say training raised MOTS-c, that high MOTS-c made people fitter, or that something else (genetics, diet, training history) drives both.
- Tiny sample. Ten people per group, all young males. The findings say nothing definitive about women, older adults or people with metabolic disease.
- Wide spread in the sedentary group. Its standard deviation (about 99 pg/mL) is large, so individual values overlap and group averages hide a lot.
- Circulating levels only. The study measured natural serum MOTS-c. It tested no injected peptide, no doses and no timing.
- Correlation is not mechanism. Strong r values in 30 people can be inflated by comparing extreme groups such as elite athletes and sedentary controls.
Takeaways
1. Training is associated with higher MOTS-c in your own body. The most defensible reading is that fitter people in this sample had higher endogenous MOTS-c. If MOTS-c is part of how exercise benefits the body, you may already be producing more of it by training. This study cannot prove that, but it fits the "exercise-responsive" description.
2. This study gives no basis for dosing or timing. The paper has no dosing, injection schedule or intervention data. Any dose or timing protocol you see online cannot be drawn from this work. Anyone wanting to know whether injected MOTS-c does anything in humans needs controlled trials, which this is not. Animal and lab studies on the peptide are preclinical background and shouldn't be assumed to carry over to people.
3. Who is this for? Based on the evidence here, nobody in particular. The study is descriptive and does not identify a group that should use the peptide. Higher natural levels in athletes do not show that raising levels artificially would give non-athletes the same benefits. Athletes' MOTS-c was embedded in a whole physiology shaped by years of training.
4. Regulatory context (not from the paper). The study says nothing about legal status. To my knowledge MOTS-c is not an approved medicine, but check current regulatory status yourself. Competitive athletes should not assume it is permitted and should check the current WADA Prohibited List or ask their anti-doping organization before using any research peptide. I cannot confirm from the source how it is currently listed.
5. The practical bottom line. Aerobic fitness showed the clearest relationship with MOTS-c here, and VO2max is something you can train. Regular exercise is a well-established way to improve it, with no injection required.
The bigger picture
The study fits a growing view that mitochondria send signals that coordinate whole-body metabolism, and that exercise changes those signals. What it cannot do is show that adding the signal from outside reproduces the effect of the training behind it. The most useful next steps would be longitudinal studies that track MOTS-c as people begin training, and randomized trials in larger and more diverse groups. Until then, the 59% figure is better read as a measure of how different athletes' biology is than as a case for supplementation.